<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336159">
  <stage>Registered</stage>
  <submitdate>7/12/2010</submitdate>
  <approvaldate>13/12/2010</approvaldate>
  <actrnumber>ACTRN12610001088033</actrnumber>
  <trial_identification>
    <studytitle>Evaluating the impact of a training-and-communication network program in nephrology to facilitate the detection and management of drug-related problems by community pharmacists.</studytitle>
    <scientifictitle>Evaluating the impact of a training-and-communication network program (ProFiL : "Programme de Formation et de Liaison" ) in nephrology to facilitate the detection and management of drug-related problems by community pharmacists: A multicenter cluster randomized controlled trial</scientifictitle>
    <utrn />
    <trialacronym>ProFiL</trialacronym>
    <secondaryid>There is no secondary IDs</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic kidney disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>For the studied year, the intervention will includes: 1) a Web-based interactive training program for community pharmacists on the prevention, detection and management of highly relevant DRPs in CKD patients, as defined by the PAIR criteria, as well as a Web-discussion forum once at the start of the study; 2) a communication-network program to facilitate the transfer of clinical information between the predialysis clinic and community pharmacists, when needed by the pharmacist during the stydied year; and 3) a seamless-care service offered to community pharmacists by predialysis pharmacists and/or nurses when needed by the pharmacist during the stydied year. 

1) Web-based interactive training program: It is entirely based on the PAIR criteria and is specifically designed to: a) familiarize community pharmacists with the PAIR criteria; and b) propose a systematic approach to detect/prevent/managed highly relevant DRPs included in the PAIR criteria. The Web-based program lasts about 60 minutes. After a brief overview of the pathophysiology of CKD, the 8 categories of the PAIR criteria are presented. Thereafter, 2 case studies are presented and the pharmacists are asked to consider each category of the PAIR criteria to detect and manage highly relevant DRPs and to complete a pharmaceutical opinion. As in real life, to do so, pharmacists have access to various tools and sources of information available within the ProFiL program: a) ProFiL clinical guide; b) ProFiL clinical summary including a list of health problems and medications as documented by the nephrologist as well as the GFR or CrCl result); c) pharmacy chart; d) direct interview with patient; and e) seamless-care service. The clinical guide includes all the information presented in the Web-based program, including the PAIR criteria, along with several clinical tools designed to facilitate the detection and management of highly relevant DRPs.
In this study, a Web discussion forum will be made available to ProFiL pharmacists. The seamless-care pharmacists will be responsible for preparing electronic case studies. Each one will present an actual ProFiL patient with highly relevant DRPs and describe its management within the ProFiL program. Pharmacists will be invited to comment on a Web fo-rum and will have the opportunity to ask questions and discuss issues of interest to them.
2) Communication-network program: It is designed to facilitate the transfer of clinical information between pharmacies and predialysis clinics. For each ProFiL patient, the community pharmacist will receive a clinical summary at baseline and month-12. It will include: a) a list of the patients medications as documented in the predialysis clinic chart; b) a list of the patients health problems; and c) the patients GFR or CrCl. The pre-dialysis clinicians (nephrologists, nurses and/or pharmacists) will be responsible for updating the list of medications and health problems. In addition, a pharmaceutical opinion form was specifically developed for CKD patients to facilitate the work of community pharmacist. 
3) Seamless-care service: It will be offered from Monday to Friday during regular working hours by predialyis pharmacists and/or nurses from each clinic. Seamless-care clinicians will act as resource persons to answer questions from community pharmacists. They will also facilitate communication between the predialysis clinic and the community pharmacies. They will receive a copy of each pharmaceutical opinion, ensure that the community pharmacists recommendations are considered and provide appropriate feedback to the community pharmacist. 
During the study, all seamless-care clinicians will record their interventions in a diary. For each communication they will record: a) the date; b) initials and number of patient; c) the initiator of the contact (pharmacist or seamless-care clinician); and d) a brief description of the discussion.</interventions>
    <comparator>Usual care (UC) community pharmacists will not be able to access the Web-based training program, clinical guide, and discussion forum; the communication-network program; and the seamless-care service. However, at the end of the study, they will be invited to complete the training program and will be given a copy of the clinical guide</comparator>
    <control>Active</control>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Compare the mean change in the number of highly relevant DRPs per patient, as defined by the PAIR criteria.</outcome>
      <timepoint>Between the baseline and the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The annual rate of DRPs resolution and appearance (as defined by the PAIR criteria).</outcome>
      <timepoint>Between the baseline and the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of patients having at least one highly relevant DRP.</outcome>
      <timepoint>At the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The annual mean number of pharmaceutical opinions issued per patient.</outcome>
      <timepoint>Between the baseline and the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of pharmacist recommendations implemented.</outcome>
      <timepoint>Between the baseline and the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The mean changes in kidney disease progression indicators (GFR, proteinuria) and CVD risk factors (low-density lipoprotein cholesterol, systolic and diastolic blood pressure, and glycosylated hemoglobin).</outcome>
      <timepoint>Between the baseline and the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of patients on dialysis.</outcome>
      <timepoint>At the month-12 evaluations in ProFiL and UC patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of comunity pharmacist who complete the Web-based interactive training program.</outcome>
      <timepoint>12 months after pharmacist entering the study.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean number of visits per pharmacist to Web discussion forum.</outcome>
      <timepoint>Between the baseline and the month-12 evaluations in ProFiL and UC pharmacists.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The change in knowledge/clinical competencies of pharmacists.</outcome>
      <timepoint>Between the baseline and the month-12 evaluations.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The satisfaction of ProFiL pharmacists on the Web-based interactive training program and Web discussion forum.</outcome>
      <timepoint>At the month-12 evaluations.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of DRPs categorised according to their level of severity.</outcome>
      <timepoint>At month-12 evaluations.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients: 1) have moderate (GFR: 30-59 ml/min/1.73 m2) or severe (GFR: 15-29 ml/min/1.73 m2) CKD based on the last laboratory test result performed; 2) are at least 18 years old; and 3) speak and read French or English; 4) have a eligible current community pharmacy that agrees to participate; 5) agree to continue being followed by their current community pharmacy for the duration of the study; and 6) are able to understand the study and provide informed consent. Patients will be excluded if they have a GFR &lt; 15 ml/min/1.73 m2 or &gt;59 ml/min/1.73 m2. Community pharmacy: 1) for pharmacies delivering &gt;250 prescriptions per day: at least 60 hours are covered by participating pharmacists; OR for  pharmacies delivering = 250 prescriptions per day at least 35 hours are covered by participating pharmacists; OR for pharmacies opened less than 7 days a week  at least 50% of the opening hours are covered by participating pharmacists; 2) a pharmacist agrees to become in charge of the project in his/her pharmacy; 3) all participating pharmacists agree to complete the training program if assigned to the ProFiL group; 4) pharmacists agree to keep a copy of all pharmaceutical opinions issued during the study and to provide a copy of the patients pharmacy chart for the period covering the 12 months prior and after the baseline; 5) pharmacists working in more than one participating pharmacies agree to be assigned to the pharmacy where he/she is working most of the time; 6) a pharmacy can not recruit more than 20 patients. Finally, each participating pharmacy can only be randomized once.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients with a GFR less than 15ml/min/1,73m2 or more than 59ml/min/1,73m2 having dialysis at enrollment. All patients not fulfilling the inclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/10/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>454</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Canadian Institutes of Health Research</primarysponsorname>
    <primarysponsoraddress>Room 97, 160 Elgin Street, Adress locator: 4809A Ottawa, (Ontario) K1A 0W9</primarysponsoraddress>
    <primarysponsorcountry>Canada</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Cercle du doyen</fundingname>
      <fundingaddress>Faculty of pharmacy
University of Montreal
C.P. 6128, Succ. Centre-ville
Montreal, Quebec, H3C 3J7</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Amgen Canada</fundingname>
      <fundingaddress>6775, Financial Drive, bureau 100
Mississauga, Ontario, L5N 0A4</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Reseau Quebecois de recherche sur l'usage du medicament</fundingname>
      <fundingaddress>Unite de recherche en sante des populations
Centre de recherche FRSQ du CHA de Quebec
1050, Chemin Ste-Foy
Quebec (Quebec) G1S 4L8</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Canadian Institutes of Health Research</fundingname>
      <fundingaddress>Room 97, 160 Elgin Street, Adress locator: 4809A Ottawa, (Ontario) K1A 0W9</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Leo Pharma Inc.</fundingname>
      <fundingaddress>123, Commerce Valley Drive East, Suite 400 Thornhill, (Ontario) L3T 7W8</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Amgen Canada</sponsorname>
      <sponsoraddress>6775, Financial Drive, bureau 100 Mississauga, Ontario, L5N 0A4</sponsoraddress>
      <sponsorcountry>Canada</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Leo Pharma Inc.</sponsorname>
      <sponsoraddress>123, Commerce Valley Drive East, Suite 400 Thornhill, (Ontario) L3T 7W8</sponsoraddress>
      <sponsorcountry>Canada</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Cercle du doyen</sponsorname>
      <sponsoraddress>Faculty of pharmacy Universite de montreal C.P. 6128, Succ. Centre-ville Montreal, Quebec, H3C 3J7</sponsoraddress>
      <sponsorcountry>Canada</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Reseau Quebecois de recherche sur l'usage du medicament</othercollaboratorname>
      <othercollaboratoraddress>Unite de recherche en sante des populations Centre de recherche FRSQ du CHA de Quebec 1050, Chemin Ste-Foy Quebec (Quebec) G1S 4L8</othercollaboratoraddress>
      <othercollaboratorcountry>Canada</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>CONTEXT The chronic kidney disease (CKD) is an increasingly heavy burden societal. The pharmacists from pre-dialysis clinics can generally not offer pharmaceutical care constant to these customers, because of the limited resources. The Community pharmacist is thus the professional of choice to offer an effective follow-up and to collaborate in management the problems related to pharmacotherapy (PRPs). The ProFiL program is a training program and of connection in nephrology conceived in order to optimize the pharmaceutical care for the patients suffering from chronic kidney disease (CKD) without recourse to dialysis. A pilot study carried out beforehand suggests that the ProFiL program offers relevant tools to help the Community pharmacists to intervene more frequently and more effectively as for the prevention and the detection of PRPs at this population. OBJECTIVES ) To compare between groups Profile and SPH the average change of the full number of PRPs of the grid of Pharmacotherapy Analyzed in Impaired Renal function (PAIR) by patient, between the moment of the entry being studied and in 12 months of follow-up. 2) To compare between groups Profile and SPH: a) The quality of the use of the drugs (according to an analysis based on EVEN PRPs of the grid) b) The management of the pharmacoth√©rapie (according to an analysis of the pharmaceutical opinions and refusal emitted for the patient by its Community pharmacist); c) Clinical variables (according to the comparison of certain clinical parameters: blood-pressure, cholesterol-LDL, glyquee haemoglobin (HbA1c), proteinurie, glomerular flow of filtration (DFG) and/or clearance of creatinin (Clcr)); d) the proportion of DRPs categorised based on their level of severity. 3) To evaluate the program Profile itself (according to the use of the clinical tools offered to the pharmacists of the Profile group, the evolution of knowledge/competences of the pharmacists and the satisfaction of the pharmacists as for the tools offered). METHOD Estimate: Open, pilot, multicentric clinical trial (6 pre-dialysis clinics), cluster randomized and controlled by parallel plan, to evaluate the impact of the program Profile on the quality of use of drugs. Study Groups: Cluster randomized with the Profile group or group SPH in a ratio 2:1 (thus 101 pharmacies Profile, 50 pharmacies SPH). The ProFiL program comprises an aspect of Web formation and a liaison department with the private clinic of pre-dialysis. The pharmacists assigned with group SPH will have access to the ProFiL program when the study is finished. Analysis: The analysis will be done as intent-to-treat. RELEVANCE The model of collaboration between hospital and community pharmacists proposed is single, simple and rests primarily on principles of formation and communication. If it proves to be efficient, it could be used like a model of reference in the management of the chronic diseases and could be applied to other types of private clinics with ambulatory customers.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sientific and Research Ethics Committee</ethicname>
      <ethicaddress>Centre de sante et de services sociaux de Laval
1775, Rene-Laennec Blvd., Room D-S080
Laval (Quebec) H7M3L9</ethicaddress>
      <ethicapprovaldate>18/10/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Lyne Lalonde</name>
      <address>Faculty of Pharmacy, Universite de Montreal, 
Pavillon Jean-Coutu, 
2940 chemin de la Polytechnique, bureau 2238, 
Montreal (Quebec), H3T 1J4</address>
      <phone>450-668-1010 ext. 23710</phone>
      <fax />
      <email>lyne.lalonde@umontreal.ca</email>
      <country>Canada</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Lyne Lalonde</name>
      <address>Faculty of Pharmacy, Universite de Montreal, 
Pavillon Jean-Coutu, 
2940 chemin de la Polytechnique, bureau 2238, 
Montreal (Quebec), H3T 1J4</address>
      <phone>450-668-1010 ext. 23710</phone>
      <fax />
      <email>lyne.lalonde@umontreal.ca</email>
      <country>Canada</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>